Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease
The PK/TE model reliably quantified the relationship between PK and systemic TE of tozorakimab, with potential utility for predicting clinical dose-response relationships and supporting clinical dose selection.
Authors
- Chris Kell
- Magnus Åstrand (ORCID: https://orcid.org/0000-0003-2053-3413)
- Lisa Hewitt (ORCID: https://orcid.org/0000-0002-3377-6484)
- Muhammad Waqas Sadiq (ORCID: https://orcid.org/0000-0002-6112-2971)
- Fred Reid
- Monica L. Gavala (ORCID: https://orcid.org/0000-0002-7475-3393)
- Helen Killick
- N. E. White (ORCID: https://orcid.org/0000-0002-9408-3964)
- Hongtao Yu (ORCID: https://orcid.org/0000-0003-2278-4478)
- Hitesh Pandya (ORCID: https://orcid.org/0000-0003-0514-2529)
- Ian C. Scott (ORCID: https://orcid.org/0000-0003-4136-4751)
- E. Suzanne Cohen (ORCID: https://orcid.org/0000-0002-4470-1680)
- Adam Williams (ORCID: https://orcid.org/0009-0002-8127-3408)
- Eulalia Jiménez (ORCID: https://orcid.org/0009-0006-4351-8063)
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-08-25
- DOI
- https://doi.org/10.1111/bcp.16195
- Citations
- 12
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 2.89
Funders
- AstraZeneca